BackTanke Biosciences Overview

Tanke Biosciences EBIT

Tanke Biosciences's EBIT is $-170K, below the sector sector average of $2.3T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$47.67K
↑ 17.48% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$174.52K
↑ 31.59% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Tanke Biosciences (TNBI) FAQ

The latest EBIT for TNBI is $-170K as of September 2026. That compares with $-260K in the prior-year period — up 31.6% year over year. That is below the sector sector average of $2.3T. Investors often review this figure alongside Tanke Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, TNBI's EBIT moved from $-260K to $-170K — a 31.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Tanke Biosciences's operating scale or balance-sheet position.

Against its sector companies, TNBI currently prints $-170K for EBIT, while the sector average sits near $2.3T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Tanke Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-170K for TNBI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.3T. Explore the charts below for those layers of context.

After noting TNBI's EBIT ($-170K), review year-over-year change from $-260K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers